Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ruilope, LM; Agarwal, R; Anker, SD; Bakris, GL; Filippatos, G; Nowack, C; Kolkhof, P; Joseph, A; Mentenich, N; Pitt, B, , FIGARO-DKD study investigators.
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Am J Nephrol. 2019; 50(5):345-356
Doi: 10.1159/000503712
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Sourij Harald
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. PATIENTS AND METHODS: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m2 and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. CONCLUSIONS: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. TRIAL REGISTRATION: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Cardiovascular Diseases - epidemiology, etiology, prevention & control
- Diabetes Mellitus, Type 2 - complications, mortality, urine
- Diabetic Nephropathies - complications, drug therapy, mortality, urine
- Disease Progression - administration & dosage
- Double-Blind Method - administration & dosage
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Glomerular Filtration Rate - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Mineralocorticoid Receptor Antagonists - therapeutic use
- Naphthyridines - therapeutic use
- Renal Insufficiency, Chronic - drug therapy, etiology, mortality
- Research Design - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- Kidney
- Mineralocorticoid
- Diabetes
- Aldosterone
- Outcomes
- Clinical